{
  "ticker": "OPL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02961163",
  "id": "02961163",
  "pages": 37,
  "price_sensitive": false,
  "date": "20250623",
  "time": "1808",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250623/pdf/06l0tnbx7rc66q.pdf",
  "summary": "### **Material Information Summary \u2013 OPYL LIMITED (ASX: OPL)**  \n**Document Type:** Notice of General Meeting  \n\n#### **Key Resolutions & Material Information:**  \n1. **Ratification of Prior Issues (Resolutions 1, 2, 5)**  \n   - **Resolution 1:** Ratification of 25,107,195 shares issued at **$0.021/share** under ASX Listing Rule 7.1 (placement capacity).  \n   - **Resolution 2:** Ratification of 16,892,805 shares issued at **$0.021/share** under ASX Listing Rule 7.1A (additional 10% capacity).  \n   - **Resolution 5:** Ratification of 500,000 shares issued at **$0.02/share** to Peak Asset Management in lieu of fees.  \n\n2. **New Equity Issuances (Resolutions 3, 4, 7, 8, 9, 10, 11)**  \n   - **Resolution 3:** Approval to issue **35,714,286 Placement Options** (1:1 with Placement Shares, exercise price **$0.03**, 4-year expiry).  \n   - **Resolution 4:** Approval to issue **8,000,000 Broker Options** to Sandton Capital/GBA Capital (same terms as Placement Options).  \n   - **Resolutions 7 & 8:** Approval to issue shares and options to Irwin Biotech Nominees Pty Ltd (**5,561,710 shares @ $0.015 + 5,561,710 options @ $0.015**) and Maryton Australia Pty Ltd (**5,931,011 shares @ $0.015 + 5,931,011 options @ $0.015**) for loan conversions.  \n   - **Resolution 9:** Approval to issue **12,671,469 shares @ $0.015 + 12,671,469 options @ $0.015** to Director Antanas Guoga for loan conversion.  \n   - **Resolution 10:** Approval to issue **3,864,154 shares @ $0.013 + 2,000,000 options @ $0.025** to Irwin Biotech for a separate $50k loan.  \n   - **Resolution 11:** Approval to issue **10,000,000 Performance Rights** to Director Saurabh Jain (vesting tied to milestones: $100k product sales and CEO recruitment).  \n\n3. **Change of Company Name (Resolution 6)**  \n   - Proposed name change to **Pathkey.AI Limited** (ASX ticker: **PKY**).  \n\n#### **Key Dates:**  \n- **Meeting Date:** 25 July 2025 (10:30 AM AEST).  \n- **Record Date for Voting:** 23 July 2025 (10:30 AM AEST).  \n\n#### **Capital Impact:**  \n- Total potential dilution from new issuances: **~92.3M shares** (excluding option exercises).  \n- **Use of Funds:** Accelerate AI drug discovery platform (Trialkey), working capital, and loan conversions.  \n\n#### **Voting Exclusions:**  \n- Resolutions 1, 2, 5: Votes excluded from placement participants/associates.  \n- Resolutions 9, 11: Votes excluded from Director Guoga/Jain and associates.  \n\n**Note:** Omit routine procedural details; focus on capital structure, dilution, and voting thresholds.  \n\n---  \n**Formatting:** Strictly concise, action-oriented. Excludes legal boilerplate and non-material operational updates.",
  "usage": {
    "prompt_tokens": 28006,
    "completion_tokens": 747,
    "total_tokens": 28753,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-23T09:07:12.557776"
}